Investors & Media
We are a clinical stage chemoprotection oncology company focused on developing medicines to make chemotherapy safer and thereby more effective to save more patients’ lives.
ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, focusing exclusively on treating patients with p53-mutated cancers.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
November 30, 2022Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
November 10, 2022Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
November 1, 2022Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
To develop a targeted drug that prevents chemotherapy-induced side effects to help patients fight cancer more effectively with a better quality of lifeOUR VISION:
To bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy